Atlas Trials

A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy

Clinical trial NCT04150029 · TERMINATED

Trial details

NCT number
NCT04150029
Sponsor
Novartis Pharmaceuticals
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Acute Myeloid Leukemia
Start date
2020-09-01
Primary completion
2024-10-25
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.